Company Overview
Snapshot
Founded in July 2010 by Dr. Izak Daizade, UNFO Med operates with 1–10 employees. The company has developed a patented Universal Neonatal Foot Orthotics (UNFO) device, receiving FDA approval in the United States and CE mark approval in Europe.
Business overview
UNFO Med develops medical devices within the Health Tech & Life Sciences sector, specifically focusing on assistive devices and medical treatment. The company's core product is the Universal Neonatal Foot Orthotics (UNFO) device, a corrective foot brace designed for the treatment of metatarsus adductus (MTA) in newborns. This technology aims to provide an effective, safe, and stress-free alternative to traditional methods like casting, serving patients, parents, and healthcare providers in markets including the United States, Europe, and South Korea.
Strategic signal
In May 2017, UNFO Med was featured in a news article highlighting its innovative approach to helping toddlers with foot conditions. This coverage underscores the company's commitment to addressing critical needs in pediatric orthopedics and signals its potential for broader market adoption and impact in the healthcare industry.
Log in to access full profile ›Company Intelligence Q&A
- What is UNFO Med's primary product?
- UNFO Med's primary product is the Universal Neonatal Foot Orthotics (UNFO) device, a child-friendly corrective foot brace for treating metatarsus adductus (MTA) in newborns.
- When was UNFO Med founded?
- UNFO Med was founded in July 2010.
- Has UNFO Med received regulatory approvals for its device?
- Yes, UNFO Med has received FDA approval in the United States and CE mark approval in Europe for its UNFO device.
- Who founded UNFO Med?
- Dr. Izak Daizade is the founder of UNFO Med.
- In which markets does UNFO Med have clients?
- UNFO Med has clients in Israel, Italy, Africa, Ukraine, and South Korea, and its products are available in geomarkets including the United States, Europe, Brazil, India, Canada, and Australia.